BioSpace News Archive

As the United States and world continue to struggle with the ongoing effects of the COVID-19 pandemic, TRICCAR, Inc. (OTC: FOSI), announces the results of a double-blind placebo-controlled study of AVL™, its proprietary immune-support anti-viral supplement.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that President and CEO Frank Watanabe will participate in a fireside chat during the Goldman Sachs 41st Annual Global Healthcare Conference Webcast taking place June 9-11, 2020.

In preparation of product commercialization, Tangen Bioscience (Tangen) announced today that it has migrated its website from its old address: TangenBio, to a new address: https://tangenbioscience.com/.

Lantern Pharma Inc. (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, today announced the pricing of its initial public offering of 1,750,000 shares of its common stock at a public offering price

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, and Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,

Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the company has signed an agreement with inventor Dr Kalev Kask . The purpose of the agreement is to initiate a drug development collaboration for the treatment of the symptoms of Covid-19, for which a patent application will be filed. Dr Kalev Kask , a bi

In April 2020, in the midst of the COVID-19 pandemic, healthcare professional services declined 68 percent in utilization and 48 percent in revenue based on total estimated in-network amounts compared to April 2019 nationally.

Science Interactive Group (SIG) and BioDigital, Inc., two companies at the forefront of the education technology industry, have partnered to provide students and educators with more flexibility in the distance learning space

Exploratory Efficacy Data Reveal INP104 Resulted in Pain Relief in 66.3% of Patients and Pain Freedom in 38% of Patients at Two Hours After First Dose; Additionally, 16.3% of Patients Reported They Gained Initial Relief as Early as 15 Minutes At Weeks 21-24, Over 98% and 95% of Patients Who Experienced Pain Freedom at Two Hours Self-Reported No Recurrence of Migraine Symptoms or Use of Rescue Medications During the 24 and 48-Hour Periods, Respectively, After Using INP104 74%

Reflow Medical, Inc., a California-based medical device company, has enrolled the first patients in A Non-RanDomized Pilot Study of the TEmporary Spur StEnt System for the Treatment of Lesions Located in the InfraPoplitEal ARteries Using a LIMUS-base Drug-coated Balloon (DEEPER LIMUS). The OUS single center clinical trial (NCT04162418) is expected to enroll up to 30 participants and last approximately six months. It